CC BY-NC-ND 4.0 · Thromb Haemost 2020; 120(03): 515-524
DOI: 10.1055/s-0039-1701009
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials

Jeffrey I. Weitz
1  The Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Gary E. Raskob
2  College of Public Health, University of Oklahoma, Oklahoma City, Oklahoma, United States
,
Alex C. Spyropoulos
3  The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York, United States
4  The Feinstein Institute for Medical Research, New York, New York, United States
5  Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, New York, United States
,
Theodore E. Spiro
6  Thrombosis and Hematology Therapeutic Area, Clinical Development, Pharmaceuticals, Bayer U.S. LLC, Whippany, New Jersey, United States
,
Yoriko De Sanctis
7  Statistics and Data Insights, Bayer U.S. LLC, Whippany, New Jersey, United States
,
Jianfeng Xu
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
Wentao Lu
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
Eunyoung Suh
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
Domenick Argenti
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
Haitao Yang
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
John Albanese
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
Concetta Lipardi
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
,
Elliot S. Barnathan
8  Janssen Research and Development LLC, Raritan, New Jersey, United States
› Author Affiliations
Funding Bayer U.S. LLC and Janssen Research & Development LLC sponsored the MAGELLAN and MARINER trials and the analysis reported here.
Further Information

Publication History

04 October 2019

04 December 2019

Publication Date:
23 January 2020 (online)

  

Abstract

Patients with renal impairment are at higher risk of thrombosis and bleeding than those with normal renal function. The optimal rivaroxaban dose for thromboprophylaxis in acutely ill medical patients with renal impairment is unknown. MARINER and MAGELLAN were multicenter, randomized clinical trials of rivaroxaban in acutely ill medical patients. Efficacy and safety outcomes in patients with renal impairment in MARINER (7.5 mg once daily) were compared with those in patients with normal renal function in MARINER (10 mg once daily) and in a subpopulation of MAGELLAN that excluded patients at high risk for bleeding at baseline (10 mg once daily). Compared with enoxaparin/placebo in the MAGELLAN subpopulation, the relative risk (RR) of symptomatic venous thromboembolism (VTE) and VTE-related death with rivaroxaban 10 mg in patients with renal impairment (RR = 0.62; 95% confidence interval [CI] 0.27–1.44) was similar to that in those with normal renal function (RR = 0.78; 95% CI 0.44–1.40), while in MARINER, the 7.5 mg dose did not reduce the risk in patients with renal impairment (hazard ratio = 1.00; 95% CI 0.52–1.92). Major bleeding with rivaroxaban 10 mg once daily was higher in patients with renal impairment than in those with normal renal function in MAGELLAN (1.54% vs. 0.98%) and in the MAGELLAN subpopulation (0.94% vs. 0.61%). At a dose of 10 mg once daily, rivaroxaban is effective for thromboprophylaxis in acutely ill medical patients with impaired or normal renal function. The safety of this regimen is enhanced without loss of efficacy by excluding patients at high risk for bleeding, but not by using a reduced-dose strategy.

Trial Registration ClinicalTrials.gov identifiers: NCT00571649 for the MAGELLAN trial, NCT02111564 for the MARINER trial.

Authors' Contributions

All authors contributed equally to the manuscript: (1) conception and design of the work, analysis, and interpretation of the data; (2) drafting the work or revising it critically for important intellectual content including: Introduction, Methods, Results, and Discussion; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part.